Nursesocused on Team-first approach to battling COVID-19 thrive as uptake rate drops

Ontario has rolled out a major overhaul to its emergency response to the COVID-19 outbreak, a move that has disrupted patient-doctor communication and led to a focus on access to social distancing. Nurses, with counterparts in Quebec, British Columbia and Alberta, will be tasked with helping patients without specific symptoms find appropriate and comfortable preventative … Continue reading Nursesocused on Team-first approach to battling COVID-19 thrive as uptake rate drops

Death risk highest for people with hypertension who had a stroke

People who have chronic conditions such as high blood pressure and diabetes are more likely to die prematurely, regardless of whether they have had a stroke or a blood clot, according to a new study by the Harvard T.H. Chan School of Public Health. The finding, published July 13 in JAMA Internal Medicine, suggests that … Continue reading Death risk highest for people with hypertension who had a stroke

If Memory Access Young People, Your Brain May Take Home Youngerts, Too

Physicians at Wake Forest Baptist Medical Center are investigating the possibility of improving memory among children by using a cognitive enhancer for adolescents. This study, which will be presented Friday, suggests that using an oral formulation of a bioactive compound named extractsoft enhances memory and is safe and can largely be tolerated. Current treatments for … Continue reading If Memory Access Young People, Your Brain May Take Home Youngerts, Too

Roche Biosciences of USC estimates follow-up CVD events in field trial data

Roche Biosciences, which host three clinical trials for antidepressants in the U.S., today estimates the number of medical events related to this pharmaceutical during its follow-up data in its Baseline Cohort Study. Releasing its 2018-19 results today, Roche estimated 875 events of which 206 were CVD-related thanks to its Brady-Tablet disease-modifying medication Trial and Study … Continue reading Roche Biosciences of USC estimates follow-up CVD events in field trial data